Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Workshop summary: Novel biomarkers for HIV incidence assay development.

Sharma UK, Schito M, Welte A, Rousseau C, Fitzgibbon J, Keele B, Shapiro S, McMichael A, Burns DN.

AIDS Res Hum Retroviruses. 2012 Jun;28(6):532-9. doi: 10.1089/AID.2011.0332. Epub 2012 Feb 24.

2.

The NIAID Division of AIDS enterprise information system: integrated decision support for global clinical research programs.

Kagan JM, Gupta N, Varghese S, Virkar H.

J Am Med Inform Assoc. 2011 Dec;18 Suppl 1:i161-5. doi: 10.1136/amiajnl-2011-000114. Epub 2011 Aug 4.

3.

Developing high-throughput HIV incidence assay with pyrosequencing platform.

Park SY, Goeken N, Lee HJ, Bolan R, Dubé MP, Lee HY.

J Virol. 2014 Mar;88(5):2977-90. doi: 10.1128/JVI.03128-13. Epub 2013 Dec 26.

4.

"In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010.

Malaspina A, Rinaldo CR, Sekaly RP, Flores J, D'Souza PM.

Vaccine. 2011 Jun 24;29(29-30):4647-53. doi: 10.1016/j.vaccine.2011.04.035. Epub 2011 May 14.

PMID:
21571022
5.
6.

Implications of HIV PrEP trials results.

Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D; Workshop Organizing Committee.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):81-90. doi: 10.1089/AID.2010.0226. Epub 2010 Dec 12.

7.

Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals.

Young JM, Turpin JA, Musib R, Sharma OK.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):737-43. doi: 10.1089/AID.2010.0313. Epub 2011 Jan 15.

8.

Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection.

Niu MT, Jermano JA, Reichelderfer P, Schnittman SM.

AIDS Res Hum Retroviruses. 1993 Sep;9(9):913-24.

PMID:
7903045
9.

Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.

Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS.

Public Health Rep. 2005 Sep-Oct;120(5):543-8.

10.

HIV-mediated defects in immune regulation.

Milman G, D'Souza MP.

AIDS Res Hum Retroviruses. 1994 Apr;10(4):421-30.

PMID:
8068418
11.

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics.

MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166.

12.

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program.

Sanchez AM, DeMarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, Stone M, Tobler L, Keating S, Schito M, Busch MP, Gao F, Denny TN.

J Immunol Methods. 2014 Jul;409:117-30. doi: 10.1016/j.jim.2014.01.004. Epub 2014 Jan 19.

13.

Towards developing standardized protocols for evaluation of cellular mucosal immune responses - Recommendations from a DAIDS/NIH workshop, June 15-16, 2009.

Mehra V, Musib R, Schito ML.

Vaccine. 2010 Jul 5;28(30):4689-94. doi: 10.1016/j.vaccine.2010.04.092. Epub 2010 May 14.

PMID:
20470800
14.
15.
16.
17.

Human versus HIV: round 2 defeat in AIDS vaccine development.

Lu S.

Expert Rev Vaccines. 2008 Mar;7(2):151-3. doi: 10.1586/14760584.7.2.151. No abstract available.

PMID:
18324884
18.

Mechanisms of HIV/SIV mucosal transmission.

Milman G, Sharma O.

AIDS Res Hum Retroviruses. 1994 Oct;10(10):1305-12.

PMID:
7848686
19.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
20.

Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa.

White R, Chileshe M, Dawson L, Donnell D, Hillier S, Morar N, Noguchi L, Dixon D.

Clin Trials. 2011 Feb;8(1):103-11. doi: 10.1177/1740774510387170.

Supplemental Content

Support Center